Advertisement

Topics

Gliosarcoma - Pipeline Review, H1 2015

02:29 EDT 22 Jul 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Gliosarcoma - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-06-16. This 62-page report is available in PDF from $2000.

Gliosarcoma - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Gliosarcoma - Pipeline Review, H1 2015’, provides an overview of the Gliosarcoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gliosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gliosarcoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gliosarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Gliosarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Gliosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gliosarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and…

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gliosarcoma Overview 6
Therapeutics Development 7
Pipeline Products for Gliosarcoma - Overview 7
Pipeline Products for Gliosarcoma - Comparative Analysis 8
Gliosarcoma - Therapeutics under Development by Companies 9
Gliosarcoma - Therapeutics under Investigation by Universities/Institutes 10
Gliosarcoma - Pipeline Products Glance 11
Clinical Stage Products 11
Gliosarcoma - Products under Development by Companies 12
Gliosarcoma - Products under Investigation by Universities/Institutes 13
Gliosarcoma - Companies Involved in Therapeutics Development 14
Amgen Inc. 14
Burzynski Research Institute, Inc. 15
Celgene Corporation 16
Merck & Co., Inc. 17
Millennium Pharmaceuticals, Inc. 18
NewLink Genetics Corporation 19
Sanofi 20
Gliosarcoma - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
alisertib - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Antineoplaston Therapy - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CC-122 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
DNX-2401 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
indoximod - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
lonafarnib - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Oncolytic Virus to Target IL-12 for Oncology - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
plerixafor - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
rilotumumab - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
SGT-53 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Stem Cell Therapy for Glioma - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Gliosarcoma - Recent Pipeline Updates 52
Gliosarcoma - Dormant Projects 59
Gliosarcoma - Product Development Milestones 60
Featured News & Press Releases 60
Nov 26, 2013: Burzynski Clinic Presents the Successful Treatment of a Child with Recurrent Diffuse Intrinsic Pontine Gliosarcoma at the Congress 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

For more information open Gliosarcoma - Pipeline Review, H1 2015.

SKU: GMDHC6801IDB

Original Article: Gliosarcoma - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Gliosarcoma - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...